To investigate the possible associations between sleep apnea syndrome, hyperinsulinemia=insulin resistance and hyperleptinemia in subjects with different degrees of body mass index. DESIGN: To test for the presence or absence of sleep apnea syndrome in association with hyperinsulinemia=insulin resistance and hyperleptinemia. SUBJECTS: Twenty subjects with different body mass index (mean BMI 30.9 AE 4.2). MEASUREMENTS: Insulin action and plasma soluble leptin receptor were measured by euglycemic hyperinsulinemic glucose clamp and by ELISA method, respectively. Occurrence of sleep apnea syndrome was assessed by clinical and nocturnal monitoring using a validated sleep apnea recorder. RESULTS: The apnea=hypopnea index (AHI) was positively correlated with plasma soluble leptin receptor (0.76; P < 0.001) and negatively with the degree of insulin-mediated glucose uptake (r ¼ 7 0.73; P < 0.001). In a multivariate analysis AHI was associated with plasma soluble leptin receptor and insulin mediated glucose uptake independently of age, gender, BMI, plasma leptin levels and PaCO 2 . CONCLUSION: Sleep apnea syndrome is associated with plasma soluble leptin receptor and insulin resistance independently of BMI.
Introduction
Sleep apnea syndrome (SAS) is a risk factor for cardiovascular morbidity and mortality. 1 -3 Whether the link between cardiovascular mortality and SAS is direct (due to occurrence of hypoxia and hypercapnia) or mediated by the coexistence of other cardiovascular risk factor such as sympathetic nervous system (SNS) overactivity needs to be established. Because hypoxia and hypercapnia are responsible for sympathetic overactivity, 4, 5 while non-REM sleep declines SNS activity, 6, 7 one could hypothesize that elevated cardiovascular mortality in SAS may be due to a factor or factors that simultaneously alter the ventilatory control and produce sympathetic overactivity during non-REM sleep. Among the factors involved in ventilatory control and in sympathetic overactivity, plasma insulin and leptin level should be taken into account. In fact, it is widely known that elevated plasma leptin and insulin levels are associated with an increase in SNS activity. 8 -11 Moreover, several, 12 -14 even if not all studies, 15 have shown a potential link between insulin resistance and SAS. Indeed, a regulatory effect of insulin on ventilatory control has been demonstrated in streptozotocin-induced diabetic rats. 16 As far as leptin is concerned, a direct effect of leptin on the respiratory control center in the brain has been demonstrated in the C57BL=6J-Lep ob mouse, which is mutated for the gene encoding leptin. 17 Due to the relationship between SNS activity, ventilatory control and development of SAS, one can hypothesize that both plasma insulin and leptin levels play a role in the development of SAS. Since hyperinsulinemia and elevated plasma leptin levels are common findings in obesity 18, 19 that, in turn, is also frequently associated with SAS, 20 -22 the possible association among SAS, hyperinsulinemia=insulin resistance and hyperleptinemia was investigated in subjects with different degrees of body mass index (BMI).
Methods

Subjects
Twenty subjects with different BMI volunteered for the study. Exclusion criteria were smoking habit, diabetes mellitus, hypertension, cardiovascular disease and consumption of drugs affecting duration and quality of sleep, blood pressure and glucose metabolism. Glucose tolerance was preliminary assessed by oral glucose tolerance test (75 g glucose). 23 Weight and height were measured using a standard technique. None of the subjects reported significant strenuous physical activity within a period of 72 h before testing. After a clear explanation of the potential risk of the study, each volunteer gave informed consent to participate in the study, which was approved by the Ethical Committee of our Institutions. More detailed information concerning the subjects is given in Table 1 .
Study protocol
All patients underwent polysomnographic studies (Sleep Monitoring System, Compumedics, mod. P-Series PS2, Abbotsford, Australia) after a night of adaptation in the sleep laboratory. Complete polysomnographic records were obtained including oxygen saturation, nasal and oral air flow, chest movement, electroencephalogram and electrocardiogram. All variables in this study were recorded continuously. Severity of sleep apnea was defined on the basis of the apnea -hypopnea index (AHI). Apnea refers to cessation of both nasal and oral airflow, and hypopnea refers to reduction in airflow to < 50% of baseline in association with oxygen desaturation. To be considered significant, abnormal respiratory events had to persist for a minimum of 10 s or had to occur in association with an arousal and=or a decrease in oxygen saturation > 4%. The AHI indicates the number of respiratory irregularities per sleep hour and is calculated as follows: (total number of apneas þ hypopneas)=(total sleep time in minutes)Â60=1. An index of < 5 is normal, 5 -20 suggests mild sleep apnea, 20 -50 is moderate, and > 50 indicates severe sleep apnea. 24 On a different day, after an overnight fast (12 h at least), each subject underwent a euglycemic hyperinsulinemic glucose clamp. 25 During the 120 min of the glucose clamp, insulin at fixed infusion rate (1 mU=kg per min ; Humulin R, Eli Lilly, Florence, Italy) and a variable amount of glucose (as 20% solution) were delivered. According to the method of Bonadonna et al 26 whole-body glucose disposal (WBGD) was calculated during the final 60 min of the clamp procedure according to the following formula: WBGD ¼ glucose infusion rate þ pool correction, as described elsewhere. 27, 28 In the basal state (from 7 60 to 0 min) and during the last 60 min of the clamp procedure, indirect calorimetry was used to estimate substrate oxidation. 29 A computerized open-circuit system to measure gas exchange through a 25 l PVC plastic canopy (PFT ERGO, Rome, Italy) was used. The monitor had a precision of 2.6% for oxygen and 2.1% for carbon production. Protein oxidation was calculated from urea nitrogen excretion before and at the end of the glucose clamp procedure, corrected for the changes in urea pool. 29 Substrate oxidation rate was calculated from the oxygen consumption, the carbon oxide production, and the nitrogen urinary excretion rate according to Ferrannini. 29 Nonoxidative glucose metabolism (NOGM) was calculated as difference between WBGD and oxidative glucose metabolism (Gox) calculated by indirect calorimetry. 29 
Analytical methods
Plasma glucose was immediately determined by plasma glucose method (Autoanalyzer, Beckman Coulter Inc., Fullerton, CA, USA). Blood samples for insulin measurements were collected in heparinized tubes. After centrifugation, plasma insulin concentration were determinate by RIA (Sorin Bolmedical, Milan, Italy). Plasma leptin and soluble form of leptin receptor levels were measured by ELISA (BioVendor Laboratory Medicine, Czech Republic; intrassay CV ¼ 11.1 AE 2.1%).
Calculation and statistical analysis Mean arterial blood pressure was calculated as diastolic blood pressure plus one-third pulse pressure. BMI was calculated as . To approximate normal distribution, plasma leptin, plasma soluble leptin receptor and plasma insulin concentration were log-trasformed (for all calculations) and then back-transformed (for presentation of the results). All results are means AE s.d. Pearson's simple correlation allowed study of the association between two variables. Multivariate linear regression analyses allowed testing of the independent association of AHI with age, gender, BMI plasma leptin and soluble leptin receptor levels, WBGD and PaCO 2 as well as calculation of the independent contribution of each covariable to the AHI variability. All calculations were made on an IBM PC by SPSS 10 (SPSS, Chicago, IL, USA).
Results
All subjects were normotensive and had a normal glucose tolerance. In the whole group of subjects (n ¼ 20) BMI correlated positively with fasting plasma triglyceride (r ¼ 0.67; P < 0.001), insulin (r ¼ 0.71; P < 0.001), leptin (r ¼ 0.64; P < 0.002), soluble leptin receptor (r ¼ 0.60; P < 0.005) levels, and inversely with WBGD (r ¼ 7 0.45; P < 0.04), Gox (r ¼ 7 0.48; P < 0.03) and NOGM (r ¼ 7 0.44; P < 0.05).
As far as AHI is concerned, it correlated with BMI, WBGD, plasma leptin and plasma soluble leptin receptor (Figure 1 ) as well as with plasma insulin levels, Gox, pO 2 and pCO 2 ( Figure 2) . No correlation between AHI and plasma glucose levels, NOGM, heart rate, mean arterial blood pressure was found (data not shown).
For evaluation of an independent association of AHI with plasma soluble leptin receptor a multivariate analysis was made ( Table 2 ). In such tests AHI was the dependent variable, while age, gender, plasma soluble leptin receptor, plasma leptin levels, WBGD, BMI and PaCO 2 were the independent variables. Such a model explained 95% of the AHI variability with plasma soluble leptin receptor, PaCO 2 and WBGD (Table  2) . Interestingly, PaCo 2 , plasma soluble leptin receptor and WBGD explained 51, 23 and 13% of the AHI variability, respectively.
Discussion
Our study demonstrated that SAS, evaluated as AHI, is associated with plasma soluble leptin receptor concentration and degree of insulin resistance independently of BMI. SAS is a common finding in obese subjects and it seems to be a consequence of increased visceral fat accumulation. 20 -22 Nevertheless, the exact mechanisms underlying the increase of SAS in obese patients are still debated. Since obesity has been associated with a high degree of insulin and hyperleptinemia, a possible impact of those factors on the genesis of SAS cannot be ruled out.
Conflicting data have been reported regarding the relationship between insulin resistance and SAS. Tiihonen et al 14 reported an association between insulin resistance and SAS in obese subjects with variable degree of glucose intolerance or diabetes mellitus. Brooks et al 13 showed improved insulin action in obese diabetic population with clinical features of SAS, following 4 months of continuous nasal positive airway Sleep apnea syndrome, soluble leptin receptor and insulin resistance D Manzella et al pressure treatment. Vgontzas et al 30 found a strong association among SAS, insulin resistance and leptin concentration in obese subjects with SAS, but not in those without SAS. These associations were also independent of BMI. 30 In contrast, Stoohs et al 15 showed the relationship between insulin resistance and disordered sleep entirely dependent on body mass. Nevertheless, overweight and obesity are also characterized by a rise in plasma leptin level which, in turn, has a modulator role on central nervous system and ventilatory control. 17 Our study confirms Vgontzas' results. In fact, SAS was correlated with WBGD and plasma insulin and provides evidence that plasma soluble leptin receptor concentration is associated with SAS independently of PaCO 2 , BMI and degree of insulin resistance. Nevertheless, some recent studies have debated the relationship between plasma soluble leptin receptor concentration and leptin resistance. In fact, in human subjects with complete leptin resistance, soluble leptin receptor levels have been shown to be very high because of a mutation responsible for exclusive production of extracellular receptors;
31 therefore, such a pathological observation cannot be assumed in human subjects with common obesity. 31 Thus, such pathophysiological discrepancy needs to be addressed in more specific studies. Nevertheless, if one accepts that the plasma soluble leptin receptors a circulating marker of leptin resistance, 32 -34 a possible impact of leptin on SAS is demonstrated by the evidence of a regulatory effect of circulating leptin levels on ventilatory control in mice. In fact, it is been reported that leptin deficiency in C57BL=6J-Lep ob mouse 17 is associated with an elevated PaCO 2 and hypoventilation. 17 On the other hand, leptin replacement in those mutant mice is accompanied by a significant increase in ventilation through central neural pathways independent of weight, CO 2 production and food intake. 17 Thus, the C57BL=6J-Lep ob mouse model demonstrated that an inability to produce leptin causes an elevated PaCO 2 and a marked respiratory depression, particularly during sleep. 17 However, such a model, in which obesity is associated with an absence of functional leptin, is extremely rare in humans, 35, 36 and further studies will need to highlight the pathophysiological mechanism underlying the relationship between leptin and hypoventilation. In our study we provide evidence that subjects with SAS (AHI ! 10) are characterized by high plasma values of soluble leptin receptor with a strong correlation with AHI. Such a relationship was independent of the confounding parameters such as age, gender, BMI, plasma leptin levels, degree of insulin resistance and PaCO 2 . Nevertheless, PaCO 2 and degree of insulin resistance are also significantly and independently associated with AHI. If the association between PaCO 2 and AHI is intuitable, the independent association between degree of insulin resistance and AHI is more complex to explain and it might be due to the well known direct effect that insulin exerts on central nervous system and thus on respiratory center. 16 Furthermore, the pathophysiological interaction between degree of insulin resistance and circulating soluble leptin receptor concentration on the respiratory center is still a problem and requires further study.
In conclusion, our study demonstrates that SAS is associated with plasma soluble leptin receptor concentration and insulin resistance independently of BMI. Further studies should demonstrate whether patients with SAS are characterized by a mutation in the soluble leptin receptor responsible for leptin resistance.
